Application of chemo(radio)therapy at doses requiring hematopoietic stem cell support has been challenging in multiple myeloma (MM). Extensive clinical trials conducted over the last decade and involving many thousands of patients have shown the ability of high-dose therapy to overcome, at least in part, chemoresistance, thereby increasing the complete remission (CR) rate up to the 40% to 50% range and providing a survival prolongation of 12 to 15 months in comparison with conventional chemotherapy.
New insights into the knowledge of graft-versus-myeloma / M. Cavo. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 103:(2004), pp. 371-372. [10.1182/blood-2003-10-3660]
New insights into the knowledge of graft-versus-myeloma
CAVO, MICHELE
2004
Abstract
Application of chemo(radio)therapy at doses requiring hematopoietic stem cell support has been challenging in multiple myeloma (MM). Extensive clinical trials conducted over the last decade and involving many thousands of patients have shown the ability of high-dose therapy to overcome, at least in part, chemoresistance, thereby increasing the complete remission (CR) rate up to the 40% to 50% range and providing a survival prolongation of 12 to 15 months in comparison with conventional chemotherapy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
